Revenue Recognition - Schedule of Revenue by Product (Details) - USD ($) $ in Millions		3 Months Ended													12 Months Ended
		Dec. 31, 2018	Sep. 29, 2018	[1]	Jun. 30, 2018	[2]	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	[3]	Jul. 01, 2017	[4]	Apr. 01, 2017	[5]	Dec. 31, 2018		Dec. 31, 2017		Dec. 31, 2016
Disaggregation of Revenue [Line Items]
Net sales		$ 1,195.2	$ 1,133.1		$ 1,186.4		$ 1,217.0	$ 1,283.0	$ 1,231.3		$ 1,237.9		$ 1,194.0		$ 4,731.7	[6]	$ 4,946.2	[6]	$ 5,280.6	[6]
Active pharmaceutical ingredients
Disaggregation of Revenue [Line Items]
Net sales															0.0		55.6		78.5
CHCA
Disaggregation of Revenue [Line Items]
Net sales	[7]														2,411.6		2,429.9		2,507.1
CHCA | Cough/Cold/Allergy/Sinus
Disaggregation of Revenue [Line Items]
Net sales	[7]														492.1		483.7		454.6
CHCA | Analgesics
Disaggregation of Revenue [Line Items]
Net sales	[7]														380.6		349.8		343.5
CHCA | Gastrointestinal
Disaggregation of Revenue [Line Items]
Net sales	[7]														400.8		340.0		335.4
CHCA | Infant nutritionals
Disaggregation of Revenue [Line Items]
Net sales	[7]														423.2		413.9		427.0
CHCA | Smoking cessation
Disaggregation of Revenue [Line Items]
Net sales	[7]														296.4		297.2		308.5
CHCA | Vitamins, minerals and dietary supplements
Disaggregation of Revenue [Line Items]
Net sales	[7]														16.5		45.4		160.4
CHCA | Animal health
Disaggregation of Revenue [Line Items]
Net sales	[7]														93.9		141.3		143.7
CHCA | Other CHCA
Disaggregation of Revenue [Line Items]
Net sales	[7],[8]														308.1		358.6		334.0
CHCI
Disaggregation of Revenue [Line Items]
Net sales															1,495.9		1,491.0		1,652.2
CHCI | Cough, Cold, and Allergy
Disaggregation of Revenue [Line Items]
Net sales															384.6		372.0		348.2
CHCI | Lifestyle
Disaggregation of Revenue [Line Items]
Net sales															319.5		315.7		300.2
CHCI | Personal Care and Derma-Therapeutics
Disaggregation of Revenue [Line Items]
Net sales															273.3		269.0		269.1
CHCI | Natural Health and Vitamins, Minerals and Dietary Supplements
Disaggregation of Revenue [Line Items]
Net sales															124.4		119.5		124.5
CHCI | Anti-Parasite
Disaggregation of Revenue [Line Items]
Net sales															105.5		104.5		111.0
CHCI | Other CHCI
Disaggregation of Revenue [Line Items]
Net sales	[9]														288.6		310.3		499.2
RX
Disaggregation of Revenue [Line Items]
Net sales															$ 824.2		$ 969.7		$ 1,042.8

[1] Includes of $221.8 million and of $18.0 million

[2] Includes of $53.2 million.

[3] Includes of $3.3 million, and of $4.0 million.

[4] Includes of $18.5 million, and of $135.2 million.

[5] Includes of $12.2 million, of $21.8 million, and restructuring expense of $38.7 million.

[6] (1)    The net sales by geography is derived from the location of the entity that sells to a third party.

[7] (1)    Includes net sales from our OTC contract manufacturing business.

[8] (2)Consists primarily of feminine hygiene, diabetes care, dermatological care, branded OTC, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment.

[9] (3) Consists primarily of liquids licensed products, diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the CHCI segment.